Aiforia - Medical Image Analysis Software

The share price has taken a well-deserved 2/3 drop from a year ago, but does the valuation make any sense even now? Growth is nowhere to be seen, losses are deepening, and on top of that, it has become apparent this year that the revenue presumed to be recurring wasn’t actually recurring.

A €35m valuation for a company generating under €3m in revenue and burning around €10m of cash a year. Repeating last November’s assessment: the share price still has room to halve. It’s hard to see any future for the company other than a fire sale of what’s left or bankruptcy.

3 Likes